BI-Lilly Alliance Creates Formidable Drug Development Combine

| Jul 17, 2014

Pharma giants Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) have formed the

BI-Lilly Diabetes Alliance, a joint effort, involving the development of several drugs aimed at treating type 1 and type 2 diabetes patients.

The Alliance recently showed up in force at the 74th American Diabetes Association Scientific Sessions in San Francisco, June 13-17. It made more than 40 presentations on drugs and drug combinations now under development, including:

The presentation of six clinical abstracts for an investigational basal insulin, LY2963016, a new insulin glargine product. It is being developed for the treatment of both type 1 and type 2 patients.

The Alliance presented 17 clinical and non-clinical abstracts on the investigational compound empagliflozin; a sodium glucose cotransporter-2 (SGLT2) inhibitor under study as a blood glucose reducer in type 2 adults. Like other drugs in this fairly new class, empagliflozin blocks glucose reabsorption in the kidney by shunting some of it to the urinary tract.

Two late-breaker abstracts discussed an investigational combination empagliflozin and linagliptin (marketed in the United States as Tradjenta®) for the type 2s. Linagliptin is a DPP-4 inhibitor, which works by blocking the enzyme dipeptidyl peptidase IV. The enzyme destroys proteins that stimulate insulin-producing cells, so by inhibiting its action, linagliptin allows for greater insulin production and slows gastric emptying.

Combining the two drugs in one tablet marks the first time that a DPP-4 inhibitor and an SGLT-2 inhibitor have been brought together as a distinct type 2 therapy.

The Alliance also presented information on Jentadueto®, a linagliptin/metformin combination used to treat type 2s (it is noBI-Lilly Alliance Creates Formidable Drug Development Combine

Diabetes Health Staff

Pharma giants Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) have formed the

BI-Lilly Diabetes Alliance, a joint effort, involving the development of several drugs aimed at treating type 1 and type 2 diabetes patients.

The Alliance recently showed up in force at the 74th American Diabetes Association Scientific Sessions in San Francisco, June 13-17. It made more than 40 presentations on drugs and drug combinations now under development, including:

The presentation of six clinical abstracts for an investigational basal insulin, LY2963016, a new insulin glargine product. It is being developed for the treatment of both type 1 and type 2 patients.

The Alliance presented 17 clinical and non-clinical abstracts on the investigational compound empagliflozin; a sodium glucose cotransporter-2 (SGLT2) inhibitor under study as a blood glucose reducer in type 2 adults. Like other drugs in this fairly new class, empagliflozin blocks glucose reabsorption in the kidney by shunting some of it to the urinary tract.

Two late-breaker abstracts discussed an investigational combination empagliflozin and linagliptin (marketed in the United States as Tradjenta®) for the type 2s. Linagliptin is a DPP-4 inhibitor, which works by blocking the enzyme dipeptidyl peptidase IV. The enzyme destroys proteins that stimulate insulin-producing cells, so by inhibiting its action, linagliptin allows for greater insulin production and slows gastric emptying.

Combining the two drugs in one tablet marks the first time that a DPP-4 inhibitor and an SGLT-2 inhibitor have been brought together as a distinct type 2 therapy.

The Alliance also presented information on Jentadueto®, a linagliptin/metformin combination used to treat type 2s (it is not used with type 1 patients) currently being marketed in the United States.


t used with type 1 patients) currently being marketed in the United States.

Click Here To View Or Post Comments

Categories: , BI, Boehringer Ingelheim, Diabetes Health, Diabetes Health Magazine, diabetes life, Diabetes Medication, diabetic drugs, Eli Lilly, Health, insuline, Living with Diabetes, thriving with diabetes, \\ Diabetes


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (2)

You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 2 comments - Jul 17, 2014

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.